Carmen Doran, CEO of Helius Therapeutics, has announced that the legalization of medicinal cannabis in New Zealand has brought good news for patients who have been seeking legal access to locally grown and manufactured cannabis products for a long time. In order to export to Europe and South America, Doran emphasized that Helius is now actively seeking investment to accelerate its domestic and international growth plans.
Getting approval for medicinal cannabis products that are truly grown and manufactured in New Zealand is an important milestone for our industry, and another first for Helius. Local patients and their advocates have fought long and hard for genuinely New Zealand-made products that are both high-quality and cost-effective," she added.
Following recent legislative changes regarding medicinal cannabis and the ability for New Zealand companies to finally produce these products locally, over 3,500 practicing pharmacists in New Zealand have been urgently mandated to familiarize themselves with this compound.
New Zealand's medicinal cannabis plan
The final details of a local medicinal cannabis program were announced at the end of 2019, and since then, New Zealand officials have been working to ensure that research license holders are prepared to take the next steps. This includes applying for commercial cultivation and production licenses so that local companies can begin production.
The plan is set to launch on April 1, 2020 and is expected to have a significant impact on many patients who benefit from the drug compound. Additionally, it will expand the national economy through export opportunities and involve multiple industries in sales and production, ultimately increasing the country's GDP. The initiative will be operated through Good Manufacturing Practice (GMP) standards to ensure the quality and consistency of cannabinoid-based medicines, promoting the prescription of safe and high-quality products by doctors.
2FIRSTS will continue to keep track of this issue and provide updates on the "2FIRSTS APP". Scan the QR code below to download the app.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
